Thomas W.
- Country
- Germany
- Department
- Klinik für Gastroenterologie
Research Overview
- Safety and Efficacy of PF-08634404 as Monotherapy and in Combination with Ipilimumab in Adults with Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
- Phase II Open-Label Study of Pembrolizumab and Lenvatinib in Advanced Hepatocellular Carcinoma Refractory to Atezolizumab and Bevacizumab Therapy
- A Phase III Randomized Double-Blind Study of Pembrolizumab, Trastuzumab, and Chemotherapy in HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Data & Insights
Has run more than one trial at 164 of 403 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating advanced gastrointestinal cancers, with particular focus on gastric and gastroesophageal junction adenocarcinomas.
- Colorectal Cancer Management
- Gastroesophageal Cancer Treatment
- Pancreatic Ductal Adenocarcinoma
Their work encompasses both early-stage and metastatic disease treatments, including targeted therapies for specific genetic mutations.
Hepatobiliary Medicine
Primary focus on treating various stages of hepatocellular carcinoma and biliary tract cancers, utilizing innovative therapeutic approaches.
- Advanced Liver Cancer Therapy
- Locoregional Treatment Approaches
- Biliary Tract Cancer Management
Expertise includes both surgical and non-surgical interventions for liver malignancies.
Specialized Therapeutic Areas
The investigator works with neuroendocrine neoplasias and ADHD in adult patients, demonstrating breadth in both oncological and neurological conditions.
- Neuroendocrine Tumor Treatment
- Adult ADHD Management
- Immunotherapy Applications
Combines multiple treatment modalities including chemotherapy, immunotherapy, and targeted biological agents.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.